Furthermore, among the patients with basal-like breast cancer with an MGMT-negative phenotype, those who received CPM-containing chemotherapy exhibited an improved DFS rate compared with those who received chemotherapy without CPM. The gene discussed is MGMT; the disease is breast cancer.